Compare HCAT & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCAT | ATYR |
|---|---|---|
| Founded | 2008 | 2005 |
| Country | United States | United States |
| Employees | N/A | 59 |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.7M | 83.3M |
| IPO Year | 2019 | N/A |
| Metric | HCAT | ATYR |
|---|---|---|
| Price | $1.10 | $0.79 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 10 | 8 |
| Target Price | $2.53 | ★ $4.20 |
| AVG Volume (30 Days) | 917.1K | ★ 1.0M |
| Earning Date | 03-12-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $311,136,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.48 | N/A |
| 52 Week Low | $1.04 | $0.64 |
| 52 Week High | $5.06 | $7.29 |
| Indicator | HCAT | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 26.29 | 40.61 |
| Support Level | $1.04 | $0.67 |
| Resistance Level | $2.45 | $0.85 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 6.86 | 8.89 |
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).